Homocysteine is associated with higher risks of ischemic stroke: A systematic review and meta-analysis

Nicollas Nunes Rabelo¹, João Paulo Mota Telles¹, Leonardo Zumerkorn Pipek¹*, Rafaela Farias Vidigal Nascimento², Rodrigo Coimbra de Gusmão¹, Manoel Jacobsen Teixeira³, Eberval Gadelha Figueiredo¹

¹ Department of Neurosurgery, University of Sao Paulo, Sao Paulo, Brazil, ² Faculdade de Medicina do ABC - Centro Universitário Saude ABC, Santo Andre, Sao Paulo, Brazil

* leonardo.pipek@fm.usp.br

Abstract

Background

High levels of homocysteine (Hct) have been associated with great risks of ischemic stroke. However, some controversy still exists. We performed a systematic review and meta-analysis to compare the levels of Hct between patients with ischemic stroke and controls.

Methods

We performed a systematic literature search for articles reporting Hct levels of patients with occurrence of ischemic stroke. We employed a random-effects inverse-variance weighted meta-analytical approach in order to pool standardized mean differences, with estimation of τ² through the DerSimonian-Laird method.

Results

The initial search yielded 1361 studies. After careful analysis of abstracts and full texts, the meta-analysis included data from 38 studies, which involved almost 16 000 stroke events. However, only 13 studies reported means and standard deviations for cases and controls, and therefore were used in the meta-analysis. Those studies presented data from 5002 patients with stroke and 4945 controls. Standardized mean difference was 1.67 (95% CI 1.00–2.25, P < 0.01), indicating that Hct levels were significantly larger in patients with ischemic stroke compared to controls. Between-study heterogeneity was very large (I² = 99%), particularly because three studies showed significantly large mean differences.

Conclusion

This meta-analysis shows that patients with ischemic stroke have higher levels of Hct compared to controls. Whether this is a modifiable risk factor remains to be assessed through larger prospective cohorts.
Introduction

As a demethylated by-product of methionine, homocysteine (Hct) is considered a toxic amino acid. It is usually removed by methionine synthase in a remethylation process that uses methylcobalamin as a co-factor and 5-methyl tetrahydrofolate as a methyl donor. In the brain, Hct catabolism heavily relies on its remethylation to methionine using methylcobalamin and folate.

Since B vitamins namely vitamin B6, vitamin B12, and folate are considered as critical co-factors during catabolism process of the Hct, an increased Hct concentration (iHct) can signal a lack or deficiency of vitamin B [1]. The Hct-methionine metabolism plays a significant role especially providing a methyl donor known as S-adenosylmethionine (SAM) which is used to perform several biological reactions.

Ultimately, iHct is known to cause several damages to major brain vessels either by altering the methylation potential (SAM/SAH) or acting independently, leading to ischemic stroke [2].

Ischemic stroke has been a leading cause of mortality and morbidity across the globe, causing a significant burden to patients and families [3, 4]. There are several known factors elevating the risk of ischemic stroke, which include transient ischemic attack (TIA), arterial diseases, atrial fibrillation, improper diet and/or obesity and physical inactivity [5]. Notably, less than half of the different types of strokes can be linked to recognized causal risk factors [6, 7].

Lately, attention has been given to Hct and its role in stroke incidences or events. Hct is a type of amino acid that contains sulfur that is considered a causal risk factor for vascular diseases such as stroke. Furthermore, available empirical evidence shows that there is a positive correlation between iHct and ischemic stroke, which has helped develop practical procedures for screening and treating iHct as a modifiable risk factor [7, 8]. Nevertheless, there are still some controversies regarding the causal role of iHct in stroke, especially due to failure of vitamin B-supplementing trials in preventing strokes [9].

Apart from a meta-analysis by Zhang et al. (2020) [10] particularly focused on the Chinese population, to the best of our knowledge, the last broad scope meta-analysis on the subject was published in 2014 by He and colleagues [11]. Therefore, we carried out a systematic review and meta-analysis to compare the levels of Hct between patients with ischemic stroke and controls. This systematic review included the largest number of studies until now, with a significant number of different populations, almost 16 000 events and a analysis based on stroke subtypes.

Methods

Literature search strategy and study design

This systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) [12]. The literature search was conducted using EMBASE and PubMed. We considered all articles up to August 13, 2022 that assessed the link between homocysteine and ischemic stroke. Keywords used include “Plasma homocysteine”, “Homocysteine”, “Hyperhomocysteinemia”, and “Ischemic Stroke” [13–24]. Other relevant articles were searched through snowballing (Fig 1). Two authors independently extracted data and performed a quality assessment of the articles using the Newcastle-Ottawa Scale (NOS). Disagreements were solved by a third author.

The search strategy used was:

(“Plasma homocysteine”[All Fields] OR “Homocysteine”[All Fields] OR “Hyperhomocysteinemia”[All Fields]) AND “Ischemic Stroke”[All Fields]—PUBMED
Homocysteine is associated with higher risks of ischemic stroke: A systematic review and meta-analysis

Fig 1. Flow diagram. PRISMA flow diagram of literature search strategy.

https://doi.org/10.1371/journal.pone.0276087.g001
Inclusion and exclusion criteria
The inclusion criteria were articles published in English about Hct concentrations in patients with ischemic stroke and controls. Randomized controlled trials (RCTs) and cohort studies were included in our systematic review. Characteristics of included studies are shown in Table 1. Articles were excluded if they were reviews, meta-analyses, letters, case reports, and articles in which Hct levels were not reported [1].

Data collection, data extraction, and quality assessment
Two researchers independently extracted demographic data, number of cases and controls, Hct level and corresponding dispersion measures (standard deviations or confidence intervals). The NOS was used to perform quality assessment. The control population used by the individual studies was analyzed to avoid comparison with other cerebrovascular diseases [14–17].

Statistical analysis and literature search
We employed a random-effects inverse-variance weighted meta-analytical approach in order to pool standardized mean differences, with estimation of $\tau^2$ through the DerSimonian-Laird method. Due to the large heterogeneity, random-effects models were used to calculate the standardized mean difference (SMD) with 95% confidence intervals (CI). Standard error funnel plots were used to assess publication bias, and sensitivity analyses were performed to evaluate the results after removing potential outliers. All analyses were performed using R (R Foundation for Statistical Computing Vienna, Austria, 2018).

Results
Systematic review
The initial search yielded 1361 studies (Fig 1). Studies were categorized as either prospective or retrospective if the blood sample used to assess Hct was collected before or after the stroke event respectively. After careful analysis of abstracts and full-texts, the meta-analysis included data from 38 studies, which involved almost 16 000 stroke events [8, 25–31].

Data for all 38 studies regarding year of publication, country, study design, method for detecting homocysteine, number of patients, mean homocysteine in each group, enrollment period and main finding is presented in Table 1. However, only 13 studies reported means and standard deviations for cases and controls, and therefore were used in the meta-analysis. Those 13 studies presented data from 5002 patients with stroke and 4945 controls.

Meta-analysis
The results of the meta-analysis are shown in Fig 2. The standardized mean difference was 1.67 (95% CI 1.09–2.25, $p < 0.01$), indicating that homocysteine levels were significantly higher in patients with ischemic stroke compared to controls. Between-study heterogeneity was very large ($I^2 = 99\%$), particularly because two studies showed significantly large mean differences.
Table 1. Studies reporting homocysteine levels in patients with ischemic stroke.

| First Author | Year | Country | Design of study | Type of study | Detecting Method | Number of Patients With IS | Number of Control Group | IS Group—Hct, mmol/L, MEAN (SD) | Control–Hct, mmol/L, MEAN (SD) | Enrollment period | Note |
|--------------|------|---------|-----------------|---------------|------------------|--------------------------|------------------------|---------------------------------|-------------------------------|----------------|------|
| Zhou [25]    | 2022 | China   | Prosp           | Case-cohort   | NI               | 3070                     | 3070                    | 14.1 (7.8)                     | 13.4 (8.2)                    | 2016–2018       | Elevated tHcy is the second most important contributor and acts additively with SBP to increase the risk of the first stroke |
| Shademan [26]| 2021 | Turkey  | Retro           | Case-control  | ELISA            | 120                      | 120                    | 16.1 (1.20)                     | 13.2 (0.82)                    | 2019–2020       | Homocysteine were significantly higher in IS patients than in the control group. |
| Hultdin [38] | 2011 | Sweden  | Retro           | NI            | NI               | 321                      | 397                    | 12.8±5.6 mmol/L                | 12.7±7.7 mmol/L                | 1986–1999       | Noticed association between iHct and HS, but not between iHct and IS. |
| Hogeveen [40]| 2002 | Netherland | Retro          | Case-control  | NI               | 11                       | 94                     | 8.6 (4.0–16.0) mmol/L          | 7.4 (4.8–18.0) mmol/L          | 1993–2000       | iHct was associated to HS and IS in newborns |
| Hongli [42]  | 2006 | China   | Retro           | Case-control  | HPLC             | 126                      | NI                     | 17.5±10.9 mmol/L               | NI               | NI  | Included association between IS and iHct to IC stenoses. Didn’t include control group. |
| Verhoef [43] | 1994 | United States | Prosp       | Case-series    | NI               | 109                      | 427                    | 11.1±4.0 mmol/L                | 10.6±3.4 mmol/L                | 1982–1984       | Noticed difference between groups without SS (p = 0.12) |
| Kelly [33]   | 2004 | United States | Prosp       | Case-series    | FPA              | 156                      | 118                    | 10.1 mmol/L                    | 10.33 mmol/L                  | 2003            | Used geometric mean to calculate Hct. Without SS |
| Chao-Zhi [44]| 2015 | China   | Prosp           | Case-series    | Standard laboratory methods | 226 | NI | 15.6 (12.2 ± 23.2) mmol/L | NI | 2012–2013 | Didn’t include control group. |
| Hyung-Min [45]| 2014 | South Korea | Retro          | Case-control  | NI               | 396                      | NI                     | 11.4±4.7 mmol/L                | NI               | 2013 | Didn’t include control group. |
| Weikert [46] | 2007 | Germany | Retro           | Case-control  | NI               | 188                      | 779                    | 9.7 (8.4–11.6) mmol/L          | 8.4 (6.8–10.2) μmol/L          | 1994–1998       | NI  |
| Zhihong [47] | 2015 | China   | Prosp           | Case-series    | Nephelometric technology | 3799 | NI | 16.9±12.5 mmol/L          | NI               | 2005–2011 | Didn’t include control group. |

(Continued)
| First Author | Year | Country | Design of study | Type of study | Detecting Method | Number of Patients With IS | Number of Control Group | IS Group—Hct, mmol/L, MEAN (SD) | Control–Hct, mmol/L, MEAN (SD) | Enrollment period | Note |
|-------------|------|---------|----------------|---------------|------------------|---------------------------|------------------------|-------------------------------|-------------------------------|-----------------|------|
| Moghaddasi [49] | 2010 | Iran | Retro | Case-control | HPLC | 82 | 60 | 21.1 (9.8) mmol/L | 13.5 (3.2) mmol/L | 2009 | NI |
| Yuetao [70] | 2010 | China | Prosp | Case-cohort | HPLC | 377 | 106 | 21.0 (12.8) mmol/L | 18.7 (11.2) mmol/L | 2007–2008 | Used TIA patients as group control |
| Yan [65] | 2017 | China | Prosp | Case-series | standard laboratory methods | 238 | NI | 16.0 (11.2–23.4) mmol/L | NI | 2014–2015 | Compared IS patients with and without depression. |
| Kelly [71] | 2002 | United States | Retro | Meta-analysis | axis homocysteine enzyme immunoassay | 1487 | 2554 | 13.51 mol/L | 11.07 mol/L | 1966–2001 | Didn’t include SD |
| Ashjazadeh [72] | 2013 | Iran | Retro | Case-control | axis homocysteine enzyme immunoassay | 171 | 86 | 16.2 mmol/L (14.8 to 17.5) | 13.5 mmol/L (12.4 to 14.6) | 2009–2010 | NI |
| Haapaniemi [73] | 2006 | Finland | Prosp | Case-series | standard competitive immunoassay method | 102 | 102 | 9.6 (11.4 ± 6.5) mmol/L | 11.6 (13.7 ± 7.1) mmol/L | 2006 | Hct was significantly lower in patients than in controls on admission |
| Niaz [74] | 2019 | Pakistan | Prosp | Case-control | | 71 | NI | 22.76±12.67 mmol/L | NI | 2017–2019 | Patients younger than 45 years old |
| Jingjuan [75] | 2017 | China | Retro | Case-control | enzymatic cycling assay | 987 | NI | 13.9 ± 6.5 mmol/L | NI | 2011–2014 | NI |
| Shan shan [67] | 2018 | China | Retro | Case-control | HPLC | 75 | 19 | 16.78±5.52 mmol/L | (13.63±5.01) mmol/L | 2016–2017 | Control group constituted of patients with atheromatous plaques in brain arteries, without IS. |
| Ling-Cong [53] | 2017 | China | Retro | Case-control | | 120 | NI | 27.57±20.17 mmol/L | NI | 2011–2014 | NI |
| Kawamoto [58] | 2002 | Japan | Retro | cross-sectional | HPLC | 44 | 47 | 14.6±5.6 mmol/L | 12.6±6.6 mmol/L | 2000 | NI |
| Ying-Li [59] | 2018 | China | Prosp | Case-series | enzymatic methods using test kits | 189 | NI | 11.90 (9.20–14.85) mmol/L | NI | 2013 | NI |
| Gungor [76] | 2018 | Turkey | Retro | Case-control | HPLC | 262 | NI | high (≥16 mol/L) in 99 patients (37.79%). Homocysteine level was normal (<14 mol/L) in 163 patients (62.21%). | NI | 2006–2016 | NI |
| Biswas [77] | 2009 | India | Prosp | Case-series | EIA | 120 | 120 | 12 (5.3–30.1) mmol/L | 11.2 (6.2–14.2) mmol/L | 2003–2007 | NI |
| Macko [78] | 2002 | Norway | Prosp | Case-series | HPLC | 49 | NI | 11.3 (±2.8 mmol/L) | NI | 2001 | NI |

(Continued)
Sensitivity analysis

Sensitivity analysis was performed to assess the results if those three outliers were to be discarded, as shown in Fig 3. When excluding Dhamija (2009), Rudreshkumar (2018) and Shademan (2021), we are left with 4645 cases and 4504 controls. The results show a significant difference, albeit much smaller (SMD = 0.23, 95% CI 0.1–0.37, p = 0.0006), and an important decrease in heterogeneity ($I^2 = 78\%$).

Publication bias

The funnel plot in Fig 4 shows an unbalanced variance distribution because of the three outliers previously mentioned: Dhamija et al. (2009) and Shademan (2021) compared serum Hct between patients with ischemic stroke and healthy controls; and Rudreshkumar et al. (2018), compared young patients with ischemic stroke and healthy controls [26, 32, 33]. The funnel plot for the sensitivity analysis is shown in Fig 5, demonstrating a much more balanced assessment regarding publication bias.

Table 1. (Continued)

| First Author | Year  | Country  | Design of study | Type of study | Detecting Method | Number of Patients With IS | Number of Control Group | IS Group—Hct, mmol/L, MEAN (SD) | Control—Hct, mmol/L, MEAN (SD) | Enrolment period | Note |
|--------------|-------|----------|-----------------|---------------|------------------|---------------------------|-------------------------|---------------------------------|---------------------------------|-----------------|------|
| Chang-yi     | 2014  | China    | Retro           | cross-sectional| automatic biochemical analyzer | 111                         | 2817                    | 17.3 (13.1–25.7) mmol/L         | 14.5 (12.0–18.5) mmol/L           | 2010–2011        | NI   |
| Rudreshkumar | 2017  | India    | Prosp           | Case-series    | HPLC              | 171                         | 249                     | 20.79 ±1.77 mmol/L             | 11.10 ±0.23 μmol/L               | 2014–2016        | NI   |
| Kalita       | 2009  | India    | Prosp           | Case-series    | NI                | 198                         | 200                     | 19.99 ±12.77 mmol/L            | 18.41 ±12.01 μmol/L              | 2004–2006        | NI   |
| Mizrahi      | 2005  | Israel   | Retro           | Case-control   | HPLC              | 113                         | NI                      | 12.99 ±7.17 mmol/L             | NI                              | 2004            | NI   |
| Sawula       | 2009  | Poland   | Retro           | Case-control   | HPLC              | 131                         | 64                      | 16.8 mmol/L                    | 10.4 mmol/L                    | 2007            | NI   |
| In-Uk        | 2008  | South Korea | Prosp          | Case-series    | NI                | 267                         | 76                      | 16.29 ±8.3 mg/dl               | 12.53 ±3.77 mg/dl               | 2006–2007        | NI   |
| Dhamija      | 2009  | India    | Retro           | Case-control   | ELISA             | 66                          | 72                      | 28.40 ±2.08 mmol/L             | 11.16 ±1.09 mmol/L               | 2008            | NI   |
| Kelly        | 2004  | United States | Prosp         | Case-series    | NI                | 156                         | 118                     | 10.1 mmol/L                    | 10.33 mmol/L                   | 2003            | NI   |
| Zhao-hui     | 2003  | China    | Retro           | Case-control   | HPLC              | 1823                        | 1832                    | 14.7 mmol/L                    | 12.8 mmol/L                    | 2000–2001        | NI   |
| Verhoef      | 1994  | United States | Retro         | Case-control   | HPLC              | 109                         | 427                     | 11.1±4.0 nmol/mL               | 10.6±3.4 nmol/mL               | 1982–1984        | NI   |
| Beynum       | 1999  | The Netherlands | Retro      | Case-control   | HPLC              | 45                          | 234                     | 8.5 mmol/L (range, 5.0 to 77 mmol/L) | 9.1 mmol/L (range, 4.3 to 20.0 mmol/L) | 1989–1997        | IS in patients from 0 to 18 years old. |
| Guan-Hui     | 2017  | China    | Prosp           | Case-series    | automated biochemistry analyzer | 86                         | 182                     | 17.45 (15.10–21.28)            | 14.45 (12.35–16.60)            | 2012–2015        | NI   |

Ischemic Stroke (IS), homocystein (Hct), standard deviation (SD), increased homocysteine (iHct), Retrospective (Retro), Prospective (Prosp), Glasgow Coma Scale (GCS), Fluorescence polarization immunoassay (FPA), highperformance liquid chromatography (HPLC), Not informed (NI), Internal Carotid (IC), Statistic Significance (SS), transient ischemic attack (TIA).

https://doi.org/10.1371/journal.pone.0276087.t001

Sensitivity analysis

Sensitivity analysis was performed to assess the results if those three outliers were to be discarded, as shown in Fig 3. When excluding Dhamija (2009), Rudreshkumar (2018) and Shademan (2021), we are left with 4645 cases and 4504 controls. The results show a significant difference, albeit much smaller (SMD = 0.23, 95% CI 0.1–0.37, p = 0.0006), and an important decrease in heterogeneity ($I^2 = 78\%$).
Subgroup analysis—Prospective studies

There were seven prospective studies detailing Hct levels for stroke and control patients. Analyzing those studies separately, Hct levels were significantly higher in stroke patients (SMD = 1.27, 95% CI 0.49–2.04, \( p = 0.0013 \)). The heterogeneity was very high (\( \tau^2 = 99\% \)) (Fig 6).

Subgroup analysis—Retrospective studies

There were six retrospective studies detailing Hct levels for stroke and control patients. Analyzing those studies separately, Hct levels were also significantly higher in stroke patients.

---

### Table 1: Study Details and Meta-Analysis Results

| Study          | Total Mean | Stroke SD | Control SD | Stroke SD | Control SD | Standardised Mean Difference | SMD  | 95%–CI | Weight |
|----------------|------------|-----------|------------|-----------|------------|-------------------------------|------|--------|--------|
| Zhou – 2022    | 3070 14.10 | 7.8000    | 3070 13.40 | 8.2000    | 0.09 [0.04; 0.14] | 8.1%                          |
| Shademan – 2021| 120 16.10  | 1.2000    | 120 13.20  | 0.8200    | 2.81 [2.45; 3.17] | 7.8%                          |
| Shan shan – 2018| 75 16.80  | 5.5000    | 19 13.60   | 5.0000    | 0.59 [0.08; 1.10] | 7.6%                          |
| Rudreshkumar – 2017 | 171 20.80 | 1.8000    | 249 11.10  | 0.2000    | 8.36 [7.76; 8.96] | 7.4%                          |
| Hultdin – 2011  | 321 12.80  | 5.6000    | 397 12.70  | 7.7000    | 0.01 [0.13; 0.16] | 8.0%                          |
| Moghaddasi – 2010 | 82 21.10  | 9.8000    | 60 13.50   | 3.2000    | 0.98 [0.62; 1.33] | 7.8%                          |
| Yuetao – 2010   | 377 21.00  | 12.8000   | 106 18.70  | 11.2000   | 0.18 [0.03; 0.40] | 8.0%                          |
| Kalita – 2009   | 198 20.00  | 12.8000   | 200 18.40  | 12.0000   | 0.13 [0.07; 0.33] | 8.0%                          |
| Dhamija – 2009  | 66 28.40   | 2.1000    | 72 11.20   | 1.1000    | 10.33 [9.05; 11.62] | 5.8%                          |
| In–UK – 2008    | 267 16.30  | 8.3000    | 76 12.50   | 3.8000    | 0.50 [0.24; 0.76] | 7.9%                          |
| Haapaniemi – 2006 | 102 11.40 | 6.5000    | 102 11.60  | 7.1000    | -0.03 [-0.30; 0.25] | 7.9%                          |
| Kawamoto – 2002 | 44 14.60   | 5.6000    | 47 12.60   | 6.6000    | 0.32 [-0.09; 0.74] | 7.7%                          |
| Verhoeff – 1994 | 109 11.10  | 4.0000    | 427 10.60  | 3.4000    | 0.14 [-0.07; 0.35] | 8.0%                          |

Random effects model 5002 4945 1.67 [1.09; 2.25] 100.0%
The heterogeneity was also very large ($I^2 = 99\%$) (Fig 7).

Subgroup analysis—TOAST stroke subtypes

There were three studies detailing Hct levels for stroke and their subtypes. Analyzing those studies separately, Hct levels were not significantly different in any subtype patients. Heterogeneity was also very large ($I^2 = 67\%$) for the large-artery atherosclerosis and small-vessel occlusion comparison. All other comparisons had a small heterogeneity ($I^2 = 0\%$) (Fig 8).

When comparing each stroke subtype with control patients, large-artery atherosclerosis (SMD = 0.31, 95% CI 0.01–0.61; $p = 0.0403$) and small-vessel occlusion (SMD = 0.29, 95% CI 0.02–0.55; $p = 0.0379$) were significantly higher in stroke patients. The heterogeneity was also very large for comparison of large-artery atherosclerosis ($I^2 = 66\%$) and small-vessel occlusion ($I^2 = 50\%$). All other comparisons had a small heterogeneity ($I^2 = 0\%$) (Fig 9).

Discussion

Stroke is emerging as an increasing public health problem, especially due to long-term disability among patients. Early detection and intervention represent the best way to protect against stroke complications. Nevertheless, there is no biomarker thus far that may correlate with stroke. High level of Hct has been found in atherosclerosis patients. Previous in vivo and in vitro studies suggest that Hct changes the endothelium to a thrombogenic phenotype.
Therefore, Hct thus has adverse effects on endothelial function, stimulates smooth muscle proliferation, and is a procoagulant, thus increasing the risk of major vascular events [10, 11, 33–49].

Patients with ischemic stroke disease have higher Hct levels than controls. Three studies identified large differences [26, 32, 33] but the vast majority of them demonstrated a tendency of higher levels of Hct in patients with stroke compared to controls, which was confirmed in the sensitivity analysis that excluded those three outliers. [9–11, 34, 50].

Therefore, Hct thus has adverse effects on endothelial function, stimulates smooth muscle proliferation, and is a procoagulant, thus increasing the risk of major vascular events [10, 11, 33–49].

Patients with ischemic stroke disease have higher Hct levels than controls. Three studies identified large differences [26, 32, 33] but the vast majority of them demonstrated a tendency of higher levels of Hct in patients with stroke compared to controls, which was confirmed in the sensitivity analysis that excluded those three outliers. [9–11, 34, 50].

| Study                | Total Mean | Stroke SD | Total Mean | Control SD | Stroke–Control Difference | SMD  | 95%–CI  | Weight |
|----------------------|------------|-----------|------------|------------|---------------------------|------|--------|--------|
| Zhou – 2022          | 3070 14.10 | 7.8000    | 3070 13.40 | 8.2000     |                           | 0.09 | [0.04; 0.14] | 14.6%  |
| Rudreshkumar – 2017  | 171 20.80  | 1.8000    | 249 11.10  | 0.2000     |                           | 8.36 | [7.76; 8.96] | 13.4%  |
| Yuetao – 2010        | 377 21.00  | 12.8000   | 106 18.70  | 11.2000    |                           | 0.18 | [-0.03; 0.40] | 14.4%  |
| Kalita – 2009        | 198 20.00  | 12.8000   | 200 18.40  | 12.0000    |                           | 0.13 | [-0.07; 0.33] | 14.5%  |
| In–Uk – 2008         | 267 16.30  | 8.3000    | 76 12.50   | 3.8000     |                           | 0.50 | [0.24; 0.76] | 14.4%  |
| Haapaniemia – 2006   | 102 11.40  | 6.5000    | 102 11.60  | 7.1000     |                           | -0.03 | [-0.30; 0.25] | 14.3%  |
| Verhoeof – 1994      | 109 11.10  | 4.0000    | 427 10.60  | 3.4000     |                           | 0.14 | [-0.07; 0.35] | 14.4%  |
| **Random effects model** 4294 | **4230** | **1.27 [0.49; 2.04]** | **100.0%** |  |

Heterogeneity: $I^2 = 99\%$, $\tau^2 = 1.0663$, $p < 0.01$

**Fig 6. Prospective studies.** Forest plot of the Standardized Mean Difference (SMD) of homocysteine levels between patients with stroke and controls for prospective studies. Hct levels were significantly higher in stroke patients (SMD = 1.27, 95% CI 0.49–2.04, $p = 0.0013$). Heterogeneity was very large ($I^2 = 99\%$).
Dai D et al. [51] establish that inverse association between Glasgow Coma Scale and Hct concentrations among patients with hemorrhagic stroke, especially in ever smokers, or in participants with higher systolic blood pressure or total cholesterol levels. Hct level may be an aggravating factor in atherosclerosis, which is positively associated with a high risk of stroke [51–57].

It is highly likely that iHct can be regarded as an aggravating factor that elevates the risk of ischemic stroke, since it triggers the necrosis of vessel walls and pathophysiology of endothelial degeneration. It can interfere with the stability of the blood-brain barrier through an excitotoxicity pathway related to NMDA channels, and it can decrease the activity of numerous essential cellular components such as Na/K ATPase, superoxide dismutase, and glutathione peroxidase [32, 58, 59].

Hct activates the transcription of the factor in nervous tissue, which increases inflammation by increasing the levels of inflammatory cytokines. The role of this molecule in epilepsy, anxiety, cardiovascular diseases and stroke leaves no doubt that it could be a key aspect of ischemic stroke pathogenesis [55, 56, 60, 61].

Hyperhomocysteinemia is currently recognized as a risk factor for ischemic stroke and human vascular disorders. Nonetheless, it is very imprecise to determine if iHct triggers the pathogenesis of the diseases or it signifies a biomarker of metabolic aberrations. Hyperhomocysteinemia changes how vascular endothelial cells function as well as activating homocysteinylation and thiolation of enzymes and plasma proteins which negatively affect the brain parenchyma and cerebrovascular. Under iHct conditions, ischemic reperfusion injury usually triggers degeneration processes as well as engage in deregulation of intracellular signaling.

Moreover, Acampa et al. [62] showed that iHct can favor atrial cardiopathy and silent episodes of atrial fibrillation occurrence with multiple mechanisms: direct effects on atrial ionic channels (electrical remodeling); biochemical damage on atrial extracellular matrix (structural remodeling); prothrombotic state, favoring atrial thrombosis and possible subsequent ischemic embolic stroke. Another study by Acampa et al. [63] also shows that iHct is associated with an alteration in electrical atrial conduction, possibly contributing, at least in part, to the increased risk of cardiac arrhythmias and, therefore, a risk factor for stroke.

Yan Ji et al. [64] demonstrated that hyperhomocysteine treatment with B vitamin supplementation significantly reduced stroke events. Factors including the folate fortification of cereal products, follow-up time, status of absorption and response to B vitamin supplementation, the existence of chronic kidney disease or high blood pressure, and the use of medication can influence the effects of B vitamin supplementation.
Shi et al. [47] observed that high plasma Hct levels in the acute ischemic stroke are strong mortality predictors in patients with severe atherosclerosis. There is a relevant, independent association with high Hct levels and the risk of mortality from patients affected with ischemic stroke. Weikert C et al. [46] suggest that vitamin B12 low plasma levels, in combination with folate low levels, probably increase the risk of ischemic Stroke. This effect may be mediated at least partly through elevations of homocysteine levels. Kwon et al. [45] proposed that high Hct increase the risk of early neurological deterioration.

It has been proven that the elevation of plasma Hct is often correlated with the development of atherosclerosis as well as the impairment of the vascular endothelium. Additionally, it

| Study       | Total Mean | Large SD | Total Mean | Small SD | Large SD | Cardio SD | Other SD | Standardised Mean Difference | SMD  | 95%–CI | Weight |
|-------------|------------|----------|------------|----------|----------|-----------|----------|-------------------------------|------|--------|--------|
| Yuetao      | 203 20.10 12.3000 | 112 23.70 14.8000 | 39 19.40 9.9000 | 0.06 [−0.28; 0.40] | 71.7% |          |        |                               |      |        |        |
| Haapaniemia | 29 13.60 9.8000  | 24 10.80 4.7000 | 0.35 [−0.22; 0.92] | 19.1% |         |          |        |                               |      |        |        |
| In–Uk       | 147 16.42 7.9400  | 120 15.94 9.8300 | 0.05 [−0.19; 0.30] | 40.1% |         |          |        |                               |      |        |        |
| Random effects model 379 | 253 |          | | −0.02 [−0.33; 0.29] | 100.0% |          |        |                               |      |        |        |

Heterogeneity: $I^2 = 67\%$, $t^2 = 0.0471$, $p = 0.05$

Fig 8. Difference in homocysteine levels for each stroke subtypes. Forest plot of the Standardized Mean Difference (SMD) of homocysteine levels between patients for each stroke subtype and controls. Homocysteine levels were not significantly different for any subtype.

https://doi.org/10.1371/journal.pone.0276087.g008

Shi et al. [47] observed that high plasma Hct levels in the acute ischemic stroke are strong mortality predictors in patients with severe atherosclerosis. There is a relevant, independent association with high Hct levels and the risk of mortality from patients affected with ischemic stroke. Weikert C et al. [46] suggest that vitamin B12 low plasma levels, in combination with folate low levels, probably increase the risk of ischemic Stroke. This effect may be mediated at least partly through elevations of homocysteine levels. Kwon et al. [45] proposed that high Hct increase the risk of early neurological deterioration.

It has been proven that the elevation of plasma Hct is often correlated with the development of atherosclerosis as well as the impairment of the vascular endothelium. Additionally, it
Fig 9. Difference in homocysteine levels for ischemic stroke subtypes and controls patients. Forest plot of the Standardized Mean Difference (SMD) of homocysteine levels between patients for each stroke subtype and controls. Patients with large-artery atherosclerosis (SMD = 0.31, 95% CI 0.01–0.61; p = 0.0403) and small-vessel occlusion (SMD = 0.29, 95% CI 0.02–0.55; p = 0.0379) had significantly higher homocysteine levels than control patients.

https://doi.org/10.1371/journal.pone.0276087.g009
triggers serine elastase synthesis in the vascular smooth muscle cells leading to elastolysis by degrading the extracellular matrix and releasing reactive oxygen species.

Fan et al. described that Hct and arterial hypertension independently correlated with moderate/severe neurological severity in stroke patients and this combination make significant correlation of interaction on neurological severity [59], and depression 3-months after stroke [65]. Shi Z et al. [47]. Demonstrate that iHct levels during the first 24 hours after admission for an acute stoke significantly mortality in 48 hours.

van Beynum et al. reported an association between occlusive vascular and stroke disease and hypehomocysteinemia [66]. In a prospective study was observed 20% higher risk of ischemic stroke in men associated with homocysteine values. High plasma Hct levels are associated with intracranial strong plaque and carotid plaque and intima-media thickness [67].

Chang-yi et al. [68] described that renal impairment was associated with a more advanced age onset, a higher frequency of previous stroke and hypertension, a higher NIHSS score at admission, lower HDL levels, and iHct compared to normal real function [68]. Renal insufficiency is a risk factor of cerebrocardiovascular events and indicates poor prognosis in many patients.

Zhang et al. (2020) reported in their metanalysis the association of iHct blood levels with acute stroke treatment patients (2243 patients) compared with controlled group (871 patients) and showed that the subtypes “small-vessel occlusion” and “large-artery atherosclerosis” are the one most associated with iHct. However this study represented just Chinese population with few patients included [10]. Our study showed similar results, with those two subtypes having significantly higher levels of iHct compared to control patients. There was no significant difference when comparing iHct levels between small-vessel and large artery subtypes.

A metanalysis performed by Homocysteine Studies Collaboration in 2002, with 30 prospective and retrospective papers, but only 1113 stroke events, concluded that elevated homocysteine is a modest independent predictor of IHD and stroke risk in healthy populations [48]. Nevertheless, Wu et al. and He Y [11, 69], demonstrated also in their metanalysis the relation between stroke events and iHct, but do not distinguish between ischemic and hemorrhagic strokes and few patients were analyzed.

Huang S et al., recently published a metanalysis showing a correlating between high levels of Hct and gender, B12 deficiency, smoking and patients who received tissue plasminogen activator treatment, but no significant differences related to age, drinking, hypertension, diabetes mellitus or hyperlipidemia in patients with stroke. However, the authors did not specify which sex, level of B12, and smoking status are correlated with Hct, decreasing the quality of the study. They also suggest that Vitamin B supplementation has a significant protective effect on recent stoke, and high levels can also predict prognosis and suggest that thrombolytic therapy may be helpful in the high-risk group. Nevertheless, they have established an arbitrary cut-off of 20 μmol/L, even the results of their analysis founded that high level of 18.6 μmol/L had 1.61 increased risk of death. This bias was not clear. This cut-off contrast with our findings because the studies analysis data shows that there were too much heterogenous with different population. Therefore, it is necessary more robust studies to reliably determine a cut-off [69].

Our meta-analysis has many strengths. To our knowledge, this is the first study that provides a comprehensive systematic review and meta-analysis of Hct levels and ischemic stroke disease, including just ischemic stroke and a large amount of data. The study involved almost 16 000 stroke events and 38 prospective and retrospective studies.

However, there are still several limitations applied to this meta-analysis, for instance, different studies especially those who adopted the retrospective design might be subjected to artifact and bias as compared to the prospective studies. A significant heterogeneity, as described in the analysis, should also prompt careful interpretation of the results. Furthermore, there is a
probability that the journals published only positive findings since the meta-analysis solely used published data. Additionally, reliability and sensitivity issues may have been related to the diverse detection methods used for elevated plasma Hct. Another important limitation is regarding the lack of data in the studies about the follow up duration.

The cross-sectional design makes it difficult to establish if the altered parameters are causally linked to stroke. Even though many of the included papers state that Hct is a risk factor for stroke, the studies performed so far do not allow this conclusion, by design, since all of them analyze a population that has already had the acute event. It is not possible, to date, to establish a cutoff for serum Hct that would confer greater risk of stroke or other cerebrovascular diseases. Ideally, larger prospective cohorts are necessary to confirm the cause-effect relationship. Additionally, since the researchers only included papers published in English, there is a high probability that some relevant studies might have been excluded.

Conclusion
This meta-analysis demonstrates that patients with stroke have higher levels of Hct compared to controls. Whether this is a modifiable risk factor remains to be assessed through larger prospective cohorts. Approaching modifiable risk factors of ischemic stroke is paramount since these are leading causes of mortality and morbidity worldwide.

Supporting information
S1 Checklist. PRISMA 2020 checklist.
(DOCX)

Author Contributions
Conceptualization: Nicollas Nunes Rabelo, Manoel Jacobsen Teixeira, Eberval Gadelha Figueiredo.
Data curation: João Paulo Mota Telles, Leonardo Zumerkorn Pipek, Rafaela Farias Vidigal Nascimento.
Formal analysis: João Paulo Mota Telles, Leonardo Zumerkorn Pipek, Rafaela Farias Vidigal Nascimento.
Investigation: Nicollas Nunes Rabelo, João Paulo Mota Telles, Leonardo Zumerkorn Pipek, Rafaela Farias Vidigal Nascimento, Rodrigo Coimbra de Gusmão.
Methodology: Nicollas Nunes Rabelo, João Paulo Mota Telles, Leonardo Zumerkorn Pipek.
Project administration: Nicollas Nunes Rabelo, Manoel Jacobsen Teixeira, Eberval Gadelha Figueiredo.
Supervision: Nicollas Nunes Rabelo, Manoel Jacobsen Teixeira, Eberval Gadelha Figueiredo.
Visualization: João Paulo Mota Telles, Leonardo Zumerkorn Pipek, Rodrigo Coimbra de Gusmão.
Writing – original draft: João Paulo Mota Telles, Leonardo Zumerkorn Pipek, Rodrigo Coimbra de Gusmão.
Writing – review & editing: Nicollas Nunes Rabelo, João Paulo Mota Telles, Leonardo Zumerkorn Pipek, Manoel Jacobsen Teixeira, Eberval Gadelha Figueiredo.
References

1. Wald NJ, Med D, Watt HC, Law MR, Weir DG, Mcpartlin J, et al. Homocysteine and Ischemic Heart Disease. Arch Intern Med. 2008; 158: 862–867.

2. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JCM, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study. Arch Intern Med. 1999; 159: 38–44. https://doi.org/10.1001/archinte.159.1.38 PMID: 9892328

3. Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schafer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990; 16: 1114–1119. https://doi.org/10.1016/0735-1097(90)90542-w PMID: 2297957

4. Pancharunnithi N, Lewis CA, Sauberlich HE, Perkins LL, Go RCP, Alvarez JO, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994; 59: 940–948. https://doi.org/10.1093/ajcn/59.4.940 PMID: 8147342

5. Lehotský J, Tothová B, Kovalská M, Dobrota D, Běloňová A, Kalenská D, et al. Role of Homocysteine in the Ischemic Stroke and Development of Ischemic Tolerance. Front Neurosci. 2016; 10: 538. https://doi.org/10.3389/fnins.2016.00538 PMID: 27932944

6. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis. 1989; 79: 139–146. https://doi.org/10.1016/0021-9150(89)90118-4 PMID: 2597223

7. Wibers DO. Unruptured intracranial aneurysms: Natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003; 362: 103–110. https://doi.org/10.1016/s0140-6736(03)13860-3 PMID: 12867109

8. Hopkins PN, Wu LL, Wu J, Hunt SC, James BC, Vincent GM, et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1995; 15: 1314–1320. https://doi.org/10.1161/01.ATV.15.9.1314 PMID: 7676943

9. Rudreshkumar KJ, Majumdar V, Nagaraja D, Christopher R. Relevance of plasma levels of free homocysteine and methionine as risk predictors for ischemic stroke in the young. Clin Nutr. 2018; 37: 1715–1721. https://doi.org/10.1016/j.clnu.2017.07.005 PMID: 28754404

10. Zhang T, Jiang Y, Zhang S, Tie T, Cheng Y, Su X, et al. The association between homocysteine and ischemic stroke subtypes in Chinese: A meta-analysis. Med (United States). 2020; 99. https://doi.org/10.1097/MD.0000000000019467 PMID: 32195946

11. He Y, Li Y, Chen Y, Feng L, Nie Z. Homocysteine level and risk of different stroke types: A meta-analysis of prospective observational studies. Nutrition, Metabolism and Cardiovascular Diseases. 2014. pp. 1158–1165. https://doi.org/10.1016/j.numecd.2014.05.011 PMID: 24984821

12. Page MJ, McKenzie JE, Bossuyt PM, Bourtou I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; n71. https://doi.org/10.1136/bmj.n71 PMID: 33782057

13. Peng H, Huang Q, Li Y, Sun S, Deng X, Liu H, et al. Study on the relationship between plasma homocysteine and acute cerebral vascular disease. J Tongji Med Univ. 2001; 20: 330–331. https://doi.org/10.1007/bf02888195 PMID: 12840927

14. Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B, et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: A multicenter case-control study in China. Stroke. 2003; 34: 2085–2090. https://doi.org/10.1161/01.STR.0000086753.00555.0D PMID: 12907815

15. Perini F, Galloni E, Bolgan I, Bader G, Ruffini R, Arzenton E, et al. Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: Stronger association with small artery disease. Neurol Sci. 2005; 26: 310–318. https://doi.org/10.1007/s10072-005-0050-7 PMID: 16388364

16. Bokhari FA, Butt A, Hassan SAA, Ghafoor F. Serial changes in plasma homocysteine in acute clinical stroke. Transl Neurosci. 2012; 3: 41–45. https://doi.org/10.2478/t13380-012-0005-1

17. Beyan C. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nephrotic syndrome. Clin Nephrol. 2013; 80: 311. https://doi.org/10.5414/CN108055 PMID: 23782547

18. Lindgren A, Brattström L, Norving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995; 26: 795–800. https://doi.org/10.1161/01.str.26.5.795 PMID: 7740569

19. Malinow MR, Ducimetiere P, Luc G. Plasma homocyst(e)ine levels and graded risk for myocardial infarction. Atherosclerosis. 126: 27–34.

20. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 1997; 96: 412–417. https://doi.org/10.1161/01.cir.96.2.412 PMID: 9244205
21. Silberberg J, Crooks R, Fryer J, Wlodarczyk J, Nair B, Guo XW, et al. Gender differences and other determinants of the rise in plasma homocysteine after L-methionine loading. Atherosclerosis. 1997; 133: 105–110. https://doi.org/10.1016/s0021-9150(97)00122-6 PMID: 9258413

22. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The atherosclerosis risk in communities (ARIC) study. Circulation. 1998; 98: 204–210. https://doi.org/10.1161/01.cir.98.3.204 PMID: 9697819

23. Verhoeof P, Stamper MJ, Buring JE. Homo-cysteine metabolism and risk of myocardial infarction. Am J Epidemiol. 143: 845–859.

24. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J, et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet. 2000; 355: 523–527. https://doi.org/10.1016/S0140-6736(99)00301-2 PMID: 10683001

25. Zhou F, Liu C, Ye L, Wang Y, Shao Y, Zhang G, et al. The Relative Contribution of Plasma Homocysteine Levels vs. Traditional Risk Factors to the First Stroke: A Nested Case-Control Study in Rural China. Front Med. 2022; 8. https://doi.org/10.3389/fmed.2021.727418 PMID: 39127734

26. Shademan B, Nourazarian A, Laghouisi D, Karamad V, Nikanfar M. Exploring potential serum levels of Homocysteine, interleukin-1 beta, and apolipoprotein B 48 as new biomarkers for patients with ischemic stroke. J Clin Lab Anal. 2021. https://doi.org/10.1002/jcla.23996 PMID: 34492129

27. Iso H, Moriyama Y, Sato S, Kitamura T, Tanigawa T, Yamagishi K, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation. 2004; 109: 2766–2772. https://doi.org/10.1161/01.CIR.0000131942.77635.2D PMID: 15159287

28. Perry IJ, Morris RW, Ebrahim SB, Shaper AG, Refsum H, Ueland PM. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995; 346: 1395–1398. https://doi.org/10.1016/s0140-6736(95)92407-8 PMID: 7475822

29. Von Eckardstein A, Rene Malinow M, Upson B, Heinrich J, Schulte H, Schonfeld R, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb Vasc Biol. 1994; 14: 460–464. https://doi.org/10.1161/01.ATV.14.3.460 PMID: 8123652

30. Graham LM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. J Am Med Assoc. 1997; 277: 1775–1781.

31. Joubran R, Asmi M, Busjahn A, Vergopoulos A, Luft FC, Jouma M. Homocysteine levels and coronary heart disease in Syria. Eur J Cardiovasc Prev Rehabil. 1998; 5: 257–261. https://doi.org/10.1177/139855589805S0174182679800500408 PMID: 9919474

32. Mizrahi EH, Fleissig Y, Arad M, Adunsky A. Plasma homocysteine level and functional outcome of patients with ischemic stroke. Arch Phys Med Rehabil. 2005; 86: 60–63. https://doi.org/10.1016/j.apmr.2004.01.031 PMID: 15640990

33. Kelly PJ, Kistler JP, Shih VE, Mandell R, Atassi N, Barron M, et al. Inflammation, Homocysteine, and Vitamin B6 Status after Ischemic Stroke. Stroke. 2004; 35: 12–15. https://doi.org/10.1161/01.STR.0000106481.59944.2F PMID: 14675445

34. Peeters AC, van Landeghem BA, Graafsmma SJ, Kranendonk SE, Hermus AR, Blom HJ, et al. Low vitamin B6, and not plasma homocysteine concentration, as risk factor for abdominal aortic aneurysm: A retrospective case-control study. J Vasc Surg. 2007; 45: 701–705. https://doi.org/10.1016/j.jvs.2006.12.019 PMID: 17398378

35. Evers S, Koch HG, Griemeyer KH, Lange B, Deufel T, Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol. 1997; 54: 1276–1282. https://doi.org/10.1001/archneur.1997.00550220074017 PMID: 9341574

36. Mansoor MA. Hyperhomocysteinaemia and premature coronary artery disease in the Chinese. Heart. 1997; 77: 390. https://doi.org/10.1136/hrt.77.4.390 PMID: 9155630

37. Robinson K, Mayer EL, Millier DP, Green R, Van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. Circulation. 1995; 92: 2825–2830. https://doi.org/10.1161/01.CIR.92.10.2825 PMID: 7586248

38. Hultdin J, Van Guelpen B, Winkvist A, Hallmans G, Weinhall L, Stegmayr B, et al. Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>C genotypes and haplotypes—Evidence for an association with hemorrhagic stroke. Clin Chem Lab Med. 2011; 49: 1555–1562. https://doi.org/10.1515/CCLM.2011.234 PMID: 21631392

39. Folate. Vitamin B12, and Risk of Ischemic and Hemorrhagic Stroke A Prospective, Nested Case-Referent Study of Plasma Concentrations and Dietary Intake. Bethany Van Guelpen.
40. Hogeveen M, Blom HJ, Van Amerongen M, Boogmans B, Van Beynum IM, Van De Bor M. Hyperhomocysteinemia as risk factor for ischemic and hemorrhagic stroke in newborn infants. J Pediatr. 2002; 141: 429–431. doi:10.1067/mpd.2002.126598 PMID: 12219068

41. Bayir A, Ak A, Özçinç Ş, Seydanoğlu A, Köstekçi ŞK, Kara F. Acute-phase vitamin B12 and folic acid levels in patients with ischemic and hemorrhagic stroke: Is there a relationship with prognosis? Neurol Res. 2010; 32: 115–118. doi:10.1179/16164109124456469620 PMID: 19825273

42. Wang H, Fan D, Zhang H, Fu Y, Zhang J, Shen Y. Serum level of homocysteine is correlated to carotid artery atherosclerosis in Chinese with ischemic stroke. Neurol Res. 2006; 28: 25–30. doi:10.1179/016164106X12445616596201 PMID: 16464359

43. Verhoef P, Hennekens CH, Rene Malinow M, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke. 1994; 25: 1924–1930. doi:10.1161/01.STR.25.10.1924 PMID: 8091435

44. Tang CZ, Zhang YL, Wang WS, Li WG, Shi JP. Serum Levels of High-sensitivity C-Reactive Protein at Admission Are More Strongly Associated with Poststroke Depression in Acute Ischemic Stroke than Homocysteine Levels. Mol Neurobiol. 2016; 53: 2152–2160. doi:10.1007/s12035-015-9186-2 PMID: 25941076

45. Kwon HM, Lee YS, Bae HJ, Kang DW. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke. 2014; 45: 871–873. doi:10.1161/STROKEAHA.113.004099 PMID: 24448992

46. Weikert C, Dierkes J, Hoffmann K, Berger K, Drogan D, Klipstein-Grobusch K, et al. B vitamin plasma levels and the risk of ischemic stroke and transient ischemic attack in a German cohort. Stroke. 2007; 38: 2912–2918. doi:10.1161/STROKEAHA.107.486068 PMID: 17885260

47. Shi Z, Guan Y, Hoo YR, Liu S, Zhang M, Lu H, et al. Elevated Total Homocysteine Levels in Acute Ischemic Stroke Are Associated with Long-Term Mortality. Stroke. 2015; 46: 2149–2125. doi:10.1161/STROKEAHA.114.009136 PMID: 26199315

48. Cotlarciuc I, Malik R, Holliday EG, Ahmadi KR, Paré G, Psaty BM, et al. Effect of genetic variants associated with plasma homocysteine levels on stroke risk. Stroke. 2014; 45: 1920–1924. doi:10.1161/STROKEAHA.114.005208 PMID: 24846872

49. Omrani HQ, Shandiz EE, Qabai M, Chaman R, Fard HA, Qaffarpoor M. Hyperhomocysteinemia, folate and B12 vitamin in iranian patients with acute ischemic stroke. ARYA Atheroscler. 2011; 7: 97–101. PMID: 22577454

50. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease: Probable Benefits of Increasing Folic Acid Intakes. JAMA J Am Med Assoc. 1995; 274: 1049–1057. doi:10.1001/jama.1995.03530130055028 PMID: 7563456

51. Dai D, Sun Y, Liu C, Xing H, Wang B, Qin X, et al. Association of Glasgow Coma Scale with Total Homocysteine Levels in Patients with Hemorrhagic Stroke. Ann Nutr Metab. 2019; 75: 9–15. doi:10.1159/000501191 PMID: 31269488

52. Warsi AA, Davies B, Morris-Stiff G, Hullin D, Lewis MH. Abdominal aortic aneurysm and its correlation to plasma homocysteine, and vitamins. Eur J Vasc Endovasc Surg. 2004; 27: 75–79. doi:10.1016/j.ejvs.2003.09.001 PMID: 14652841

53. Cong L, Zhao H, Wang Y, Li Y, Sui X. The serum homocysteine level in patients with acute ischemic stroke (AIS) after thrombolysis and its relationship with clinical outcomes. Rev Assoc Med Bras. 2018; 64: 438–442. doi:10.1590/1980-9282/64.06.438 PMID: 30304143

54. Shi Z, Liu S, Guan Y, Zhang M, Lu H, Yue W, et al. Changes in total homocysteine levels after acute stroke and recurrence of stroke. Sci Rep. 2018; 8. doi:10.1038/s41598-018-25398-5 PMID: 29725064

55. Zhou Z, Liang Y, Zhang X, Xu J, Kang K, Qu H, et al. Plasma d-dimer concentrations and risk of intracerebral hemorrhage: A systematic review and meta-analysis. Front Neurol. 2018; 9: 1–9. doi:10.3389/fneur.2018.01114 PMID: 30619067

56. Hankay GJ. Is plasma homocysteine a modifiable risk factor for stroke? Nat Clin Pract Neurol. 2006; 2: 28–33. doi:10.1038/ncpneuro0093 PMID: 16932518

57. Djuric D, Jakovljevic V, Zivkovic V, Srejovic I. Homocysteine and homocysteine-related compounds: An overview of the roles in the pathology of the cardiovascular and nervous systems. Can J Physiol Pharmacol. 2018; 96: 991–1003. doi:10.1138/cjpp-2018-0112 PMID: 30130426

58. Kawamoto R, Kajiwara T, Oka Y, Takagi Y. An association between an antibody against Chlamydia pneumoniae and ischemic stroke in elderly Japanese. Intern Med. 2003; 42: 571–575. doi:10.1002)
Fan YL, Zhan R, Dong YF, Huang L, Ji XX, Lu P, et al. Significant interaction of hypertension and homocysteine on neurological severity in first-ever ischemic stroke patients. J Am Soc Hypertens. 2018; 12: 534–541. https://doi.org/10.1016/j.jash.2018.03.011 PMID: 29678422

Sawula W, Banecka-Majkutewicz Z, Kadziński L, Jakóbiewicz-Banecka J, Wegrzyn G, Nyka W, et al. Homocysteine level and metabolism in ischemic stroke in the population of Northern Poland. Clin Biochem. 2009; 42: 442–447. https://doi.org/10.1016/j.clinbiochem.2008.12.019 PMID: 19166826

Song IU, Kim JS, Ryu SY, Lee SB, Lee SJ, shin Jeong D, et al. Are plasma homocysteine levels related to neurological severity and functional outcome after ischemic stroke in the Korean population? J Neurol Sci. 2009; 278: 60–63. https://doi.org/10.1016/j.jns.2008.11.011 PMID: 19062047

Acampa M, Lazzerini PE, Guideri F, Tassi R, Martini G. Ischemic Stroke after Heart Transplantation. J Thorac Cardiovasc Surg. 2016/02/26 . 2016; 18: 157–168. https://doi.org/10.1016/j.jtcvs.2016.02.033 PMID: 26941224

Acampa M, Lazzerini PE, Guideri F, Rechichi S, Capeccchi PL, Maccherini M, et al. Homocysteine and P wave dispersion in patients with heart transplantation. Clin Transplant. 2011; 25: 119–125. https://doi.org/10.1111/j.1399-0012.2009.01126.x PMID: 19878513

Ji Y, Tan S, Xu Y, Chandra A, Shi C, Song B, et al. Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: A meta-analysis. Neurology. 2013; 81: 1298–1307. https://doi.org/10.1212/ WNL.0b013e3182a823cc PMID: 24049135

Li Y, Cao LL, Liu L, De Qi Q. Serum levels of homocysteine at admission are associated with post-stroke depression in acute ischemic stroke. Neurol Sci. 2017; 38: 811–817. https://doi.org/10.1007/ s10072-017-2848-2 PMID: 28215036

Van Beynum IM, Smetink JAM, Den Heijer M, Te Poele Pothoff MTWB, Blom HJ. Hyperhomocysteinemia: A risk factor for ischemic stroke in children. Circulation. 1999; 99: 2070–2072. https://doi.org/10.1161/01.cir.99.16.2070 PMID: 10217643

Lu SS, Xie J, Su CQ, Ge S, Bin Shi H, Hong XN. Plasma homocysteine levels and intracranial plaque characteristics: Association and clinical relevance in ischemic stroke. BMC Neurolog. 2018; 18. https://doi.org/10.1186/s12883-018-1203-4 PMID: 30522455

Wang CY, Chen ZW, Zhang T, Liu J, Chen SH, Liu SY, et al. Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. Eur J Intern Med. 2014; 25: 538–544. https://doi.org/10.1016/j.ejim.2014.04.011 PMID: 24824758

Wu X, Zhou Q, Chen Q, Li Q, Guo C, Tian G, et al. Association of homocysteine level with risk of stroke: A dose–response meta-analysis of prospective cohort studies. Nutr Metab Cardiovasc Dis. 2020; 30: 1861–1869. https://doi.org/10.1016/j.numecd.2020.07.026 PMID: 32912796

Wang Y, Ma Y, Zhao X, Zhang W, Liu L, Wang Y, et al. Homocysteine and ischemic stroke subtype: A relationship study in Chinese patients. Neuror Res. 2010; 32: 636–641. https://doi.org/10.1179/ 0161409X12445616596445 PMID: 19660240

Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomariotigou A, et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: Results of a meta-analysis. Neurology. 2002; 59: 529–536. https://doi.org/10.1212/ WNL.59.4.529 PMID: 12196644

Ashjazadeh N, Fathi M, Shariat A. Evaluation of homocysteine level as a risk factor among patients with ischemic stroke and its subtypes. Iran J Med Sci. 2013; 38: 233–239. PMID: 24174694

Haapaniemi E, Helenius J, Soinne L, Syrjälä M, Kaste M, Tatlisumak T. Serial measurements of plasma homocysteine levels in early and late phases of ischemic stroke. Eur J Neurol. 2007; 14: 12–17. https://doi.org/10.1111/j.1468-1331.2006.01518.x PMID: 17222107

Niazi F, Aslam A, Khattak S, Waheed S. Frequency of Homocysteinemia in Young Ischemic Stroke Patients and Its Relationship with the Early Outcome of a Stroke. Cureus. 2019; 11: 5625. https://doi.org/10.7759/ cureus.5625 PMID: 31700728

Chen J, Li G, Xu Z, Zhang C, Wang Y, Xie H, et al. Elevated Plasma Homocysteine Level Increased the Risk of Early Renal Impairment in Acute Ischemic Stroke Patients. Cell Mol Neurobiol. 2017; 37: 1399–1405. https://doi.org/10.1007/s10571-017-0470-8 PMID: 28275883

Gungor L, Polat M, Ozberk MB, Avci B, Abur U. Which Ischemic Stroke Subtype Is Associated with Hyperhomocysteinemia? J Stroke Cerebrovasc Dis. 2018; 27: 1921–1929. https://doi.org/10.1016/j. jstrokecerebrovasdis.2018.02.033 PMID: 29661647

Biswa S, Ranjan R, Meena A, Akhter MS, Yadav BK, Munisamy M, et al. Homocystine Levels, Polymorphisms and the Risk of Ischemic Stroke in Young Asian Indians. J Stroke Cerebrovasc Dis. 2009; 18: 103–110. https://doi.org/10.1016/j.jstrokecerebrovasdis.2008.09.014 PMID: 19251185

Macko RF, Kittner SJ, Ivey FM, Epstein A, Sparks MJ, Hebel JR, et al. Effects of vitamin therapy on plasma total homocysteine, endothelial injury markers, and fibrinolysis in stroke patients. J Stroke Cerebrovasc Dis. 2002; 11: 1–8. https://doi.org/10.1053/jscd.2002.123968 PMID: 17903848
79. Kalita J, Kumar G, Bansal V, Misra UK. Relationship of homocysteine with other risk factors and outcome of ischemic stroke. Clin Neurol Neurosurg. 2009; 111: 364–367. https://doi.org/10.1016/j.clineuro.2008.12.010 PMID: 19185985

80. Dhamija RK, Gaba P, Arora S, Kaintura A, Kumar M, Bhattacharjee J. Homocysteine and lipoprotein (a) correlation in ischemic stroke patients. J Neurol Sci. 2009; 281: 64–68. https://doi.org/10.1016/j.jns.2009.02.341 PMID: 19285692

81. Wu GH, Kong FZ, Dong XF, Wu DF, Guo QZ, Shen AR, et al. Association between hyperhomocysteinemia and stroke with atherosclerosis and small artery occlusion depends on homocysteine metabolism-related vitamin levels in Chinese patients with normal renal function. Metabolic Brain Disease. Springer Science+Business Media New York; 2017. https://doi.org/10.1007/s11011-017-9978-3 PMID: 28261756